Grufity logo
Grufity logo
DGX

DGX - Quest Diagnostics Inc Stock Price, Fair Value and News

$231.10-4.36 (-1.85%)
Delayed as of 10 Sep 2026, 04:00 pm ET

48/100

DGX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

48/100

DGX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

DGX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

DGX Price Action

Last 7 days

-3.5%

Last 30 days

-2.7%

Last 90 days

13.8%

Trailing 12 Months

28.3%

DGX RSI Chart

DGX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

DGX Valuation

Market Cap

25.7B

Price/Earnings (Trailing)

24.15

Price/Sales (Trailing)

2.22

EV/EBITDA

16.91

Price/Free Cashflow

19.02

DGX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

DGX Fundamentals

DGX Revenue

Revenue (TTM)

11.6B

Rev. Growth (Yr)

10.21%

Rev. Growth (Qtr)

5.11%

DGX Earnings

Earnings (TTM)

1.1B

Earnings Growth (Yr)

13.48%

Earnings Growth (Qtr)

26.98%

DGX Profitability

Operating Margin

33.11%

EBT Margin

12.15%

Return on Equity

13.58%

Return on Assets

6.27%

Free Cashflow Yield

5.26%

DGX Investor Care

Dividend Yield

1.44%

Dividend/Share (TTM)

3.32

Buy Backs (1Y)

0.89%

Diluted EPS (TTM)

9.42

DGX Alerts

  • 2 major insider sales recently.
Revenue & Growth

How Quest Diagnostics Inc generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
202611.3B11.6B--
202510.2B10.5B10.8B11.0B
20249.3B9.3B9.5B9.9B
20239.6B9.5B9.3B9.3B
202210.7B10.6B10.3B9.9B
202110.3B11.1B11.0B10.8B
20207.7B7.5B8.4B9.4B
20197.5B7.6B7.6B7.7B
20187.5B7.5B7.6B7.5B
20177.5B7.4B7.4B7.4B
20167.5B7.5B7.5B7.5B
20157.5B7.6B7.5B7.5B
20147.1B7.2B7.3B7.4B
20137.3B7.2B7.2B7.1B
20127.5B7.5B7.5B7.4B
2011--7.4B7.4B
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Quest Diagnostics Inc

DGX
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
 CEO
 WEBSITEquestdiagnostics.com
 SECTORHealthcare
 INDUSTRYDiagnostics & Research
 EMPLOYEES40000

Quest Diagnostics Inc Frequently Asked Questions

DGX is the stock ticker symbol of Quest Diagnostics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Thu Sep 10 2026, market cap of Quest Diagnostics Inc is 25.65 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Thu Sep 10 2026, DGX's PE ratio (Price to Earnings) is 24.15 and Price to Sales (PS) ratio is 2.22. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DGX PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Quest Diagnostics Inc has provided 0.109 (multiply by 100 for percentage) rate of return.